Effective Date:

Monday, March 04, 2019

Test Updates

In our continuing effort to provide you with the highest quality toxicology laboratory services available, we have compiled important changes regarding a number of tests we perform. Listed below are the types of changes that may be included in this notification, effective Monday, March 04, 2019

Test Changes - Tests that have had changes to the method/ CPT code, units of measurement, scope of analysis, reference comments, or specimen requirements.

Discontinued Tests - Tests being discontinued with alternate testing suggestions.

Please use this information to update your computer systems/records. These changes are important to ensure standardization of our mutual laboratory databases.

If you have any questions about the information contained in this notification, please call our Client Support Department at (866) 522-2206. Thank you for your continued support of NMS Labs and your assistance in implementing these changes.

The CPT Codes provided in this document are based on AMA guidelines and are for informational purposes only. NMS Labs does not assume responsibility for billing errors due to reliance on the CPT Codes listed in this document.

NMS Labs
3701 Welsh Road, PO Box 433A
Willow Grove, PA 19090-0437
nms@nmslabs.com

Test Updates

Test Code	Test Name	Test Name	Method / CPT Code	Specimen Req.	Stability	Scope	Units	Reference Comments	Discontinue
54136U	8-Hydroxy Amoxapine Confirmation (Qualitative) (DUID/DRE), Urine	•	•	•	•	•			
52239U	8-Hydroxy Amoxapine Metabolite Confirmation, Urine	•	•	•	•	•			
0325U	8-Hydroxy Amoxapine, Urine	•	•	•	•	•			
0100B	Acetophenazine, Blood								•
0100SP	Acetophenazine, Serum/Plasma		•	•	•			•	
54140B	Amoxapine Confirmation (DUID/DRE), Blood		•	•	•			•	
52239B	Amoxapine Confirmation, Blood		•	•	•			•	
52239FL	Amoxapine Confirmation, Fluid		•	•					
52239SP	Amoxapine Confirmation, Serum/Plasma		•	•	•			•	
52239TI	Amoxapine Confirmation, Tissue		•						
5448B	Amoxapine and Metabolite Confirmation, Blood								•
5448SP	Amoxapine and Metabolite Confirmation, Serum/Plasma								•
5448U	Amoxapine and Metabolite Confirmation, Urine								•
9107B	Amoxapine and Metabolite Screen, Blood								•
9107SP	Amoxapine and Metabolite Screen, Serum/Plasma								•
9107U	Amoxapine and Metabolite Screen, Urine								•
0325B	Amoxapine and Metabolite, Blood		•	•	•			•	
0325SP	Amoxapine and Metabolite, Serum/Plasma		•	•	•			•	
0585B	Benzonatate, Blood		•	•	•			•	
0585SP	Benzonatate, Serum/Plasma		•	•	•			•	
0585U	Benzonatate, Urine		•	•	•				
52016U	Carbromal Confirmation, Urine			•					
1440B	Dapsone and Metabolite, Blood		•	•				•	
1440SP	Dapsone and Metabolite, Serum/Plasma		•	•	•			•	
1777B	Dipyridamole, Blood		•					•	
1777SP	Dipyridamole, Serum/Plasma		•	•				•	
1777U	Dipyridamole, Urine								•
54351U	Flecainide Confirmation (Qualitative) (DUID/DRE), Urine		•						
52047B	Flecainide Confirmation, Blood		•					•	
52047FL	Flecainide Confirmation, Fluid		•						
52047SP	Flecainide Confirmation, Serum/Plasma		•	•					

NMS Labs
3701 Welsh Road, PO Box 433A
Willow Grove, PA 19090-0437
nms@nmslabs.com

Test Updates

Test Code	Test Name	Test Name	Method / CPT Code	Specimen Req.	Stability	Scope	Units	Reference Comments	Discontinue
52047TI	Flecainide Confirmation, Tissue		•						
52047U	Flecainide Confirmation, Urine		•						
2088B	Flecainide, Blood		•					•	
2088SP	Flecainide, Serum/Plasma		•	•					
2088U	Flecainide, Urine		•						
54357B	Loxapine Confirmation (DUID/DRE), Blood		•					•	
52064B	Loxapine Confirmation, Blood							•	
52064FL	Loxapine Confirmation, Fluid			•					
52064SP	Loxapine Confirmation, Serum/Plasma				•			•	
2538B	Loxapine, Blood							•	
2538SP	Loxapine, Serum/Plasma				•			•	
52081B	Metoclopramide Confirmation, Blood		•	•	•			•	
52081FL	Metoclopramide Confirmation, Fluid		•	•					
52081SP	Metoclopramide Confirmation, Serum/Plasma		•	•	•			•	
52081TI	Metoclopramide Confirmation, Tissue		•						
52081U	Metoclopramide Confirmation, Urine		•	•					
3041B	Metoclopramide, Blood		•	•	•			•	
3041SP	Metoclopramide, Serum/Plasma		•	•	•			•	
3041U	Metoclopramide, Urine		•	•					
3092SP	Moricizine, Serum/Plasma		•	•	•			•	
3145B	Nefazodone, Blood		•					•	
3145SP	Nefazodone, Serum/Plasma		•	•				•	
3145U	Nefazodone, Urine		•	•	•				
10101U	Novel Psychoactive Substances (NPS) (Qualitative), Urine (CSA)					•			
3232B	Omeprazole / Esomeprazole, Blood	•	•	•	•	•			
3232SP	Omeprazole / Esomeprazole, Serum/Plasma	•	•	•	•	•			
54340B	Piperazine Designer Drugs Confirmation (DUID/DRE), Blood					•			
54393B	Piperazine Designer Drugs Confirmation (DUID/DRE), Blood (CSA)							•	
54340U	Piperazine Designer Drugs Confirmation (Qualitative) (DUID/DRE), Urine					•			
52373B	Piperazine Designer Drugs Confirmation, Blood					•			
52373FL	Piperazine Designer Drugs Confirmation, Fluid					•			

Test Updates

Test Code	Test Name	Test Name	Method / CPT Code	Specimen Req.	Stability	Scope	Units	Reference Comments	Discontinue
52373SP	Piperazine Designer Drugs Confirmation, Serum/Plasma					•			
52373TI	Piperazine Designer Drugs Confirmation, Tissue					•			
52373U	Piperazine Designer Drugs Confirmation, Urine					•			
52108B	Propafenone Confirmation, Blood		•	•				•	
52108FL	Propafenone Confirmation, Fluid		•	•					
52108SP	Propafenone Confirmation, Serum/Plasma		•	•				•	
52108TI	Propafenone Confirmation, Tissue		•						
52108U	Propafenone Confirmation, Urine		•	•	•				
3976B	Propafenone, Blood		•	•				•	
3976SP	Propafenone, Serum/Plasma		•	•				•	
54125U	Tiletamine Confirmation (Qualitative) (DUID/DRE), Urine			•					
52125U	Tiletamine Confirmation, Urine			•					
5664B	Trazodone Confirmation, Blood								•
5664SP	Trazodone Confirmation, Serum/Plasma								•
5664U	Trazodone Confirmation, Urine								•
9282B	Trazodone Screen, Blood								•
9282SP	Trazodone Screen, Serum/Plasma								•
9282U	Trazodone Screen, Urine								•
54187B	Trazodone and mCPP Confirmation (DUID/DRE), Blood		•	•	•	•		•	
54185U	Trazodone and mCPP Confirmation (Qualitative) (DUID/DRE), Urine	•	•	•		•			
52295B	Trazodone and mCPP Confirmation, Blood	•	•	•	•	•		•	
52295FL	Trazodone and mCPP Confirmation, Fluid	•	•	•		•			
52295SP	Trazodone and mCPP Confirmation, Serum/Plasma	•	•	•	•	•		•	
52295TI	Trazodone and mCPP Confirmation, Tissue	•	•			•			
52295U	Trazodone and mCPP Confirmation, Urine	•	•	•		•			
4535B	Trazodone and mCPP, Blood	•	•		•	•		•	
4535SP	Trazodone and mCPP, Serum/Plasma	•	•	•	•	•		•	
4535U	Trazodone and mCPP, Urine	•	•			•			
4535FL	Trazodone, Fluid		•						
4535TI	Trazodone, Tissue		•						

Effective Date:

Monday, March 04, 2019

Test Updates

Test Code	Test Name	Test Name	Method / CPT Code	Specimen Req.	Stability	Scope	Units	Reference Comments	Discontinue
0419SP	Warfarin (Qualitative), Serum/Plasma								•
4800B	Warfarin, Blood		•	•				•	
4800SP	Warfarin, Serum/Plasma		•	•				•	
54138U	Zolazepam Confirmation (Qualitative) (DUID/DRE), Urine			•					
52138U	Zolazepam Confirmation, Urine			•					
4875U	Zolazepam, Urine			•					
1138B	meta-Chlorophenylpiperazine (mCPP), Blood (Forensic)		•	•	•		•	•	
1138SP	meta-Chlorophenylpiperazine (mCPP), Serum/Plasma (Forensic)		•	•	•		•	•	
1138U	meta-Chlorophenylpiperazine (mCPP), Urine (Forensic)		•	•	•		•	•	

Test Updates

Test Changes

54136U 8-Hydroxy Amoxapine Confirmation (Qualitative) (DUID/DRE), Urine

Summary of Changes:
Test Name was changed.
Specimen Requirements were changed.
Specimen Requirements (Specimen Container) were changed.
Stability was changed.
Scope of Analysis was changed.
8-Hydroxy Amoxapine was added.
Methods/CPT Codes were changed [LC-MS/MS (80355, 80362, 80376)]
Amoxapine was removed.

Specimen Requirements: 1 mL Urine
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: None
Stability: Room Temperature: 14 day(s)
Refrigerated: 14 day(s)
Frozen (-20 °C): 14 day(s)
Scope of Analysis: Method (CPT Code): LC-MS/MS (80355, 80362, 80376): 8-Hydroxy Amoxapine

Compound Name	Units	Reference Comment
8-Hydroxy Amoxapine	ng/mL	

52239U 8-Hydroxy Amoxapine Metabolite Confirmation, Urine

Summary of Changes:
Test Name was changed.
Specimen Requirements were changed.
Specimen Requirements (Specimen Container) were changed.
Stability was changed.
Scope of Analysis was changed.
8-Hydroxy Amoxapine was added.
Methods/CPT Codes were changed [LC-MS/MS (80335)]
Amoxapine was removed.

Specimen Requirements: 1 mL Urine
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: None
Stability: Room Temperature: 14 day(s)
Refrigerated: 14 day(s)
Frozen (-20 °C): 14 day(s)

NMS Labs
3701 Welsh Road, PO Box 433A
Willow Grove, PA 19090-0437
nms@nmslabs.com

Test Updates

Test Changes

Scope of Analysis: LC-MS/MS (80335): 8-Hydroxy Amoxapine
Method (CPT Code)

Compound Name	Units	Reference Comment
8-Hydroxy Amoxapine	ng/mL	

0325U 8-Hydroxy Amoxapine, Urine

Summary of Changes:
Test Name was changed.
Specimen Requirements were changed.
Stability was changed.
Scope of Analysis was changed.
Methods/CPT Codes were changed [LC-MS/MS (80335)]
Amoxapine was removed.

Specimen Requirements: 1 mL Urine
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: None
Stability: Room Temperature: 14 day(s)
Refrigerated: 14 day(s)
Frozen (-20 °C): 14 day(s)
Scope of Analysis: LC-MS/MS (80335): 8-Hydroxy Amoxapine
Method (CPT Code)

0100SP Acetophenazine, Serum/Plasma

Summary of Changes:
Specimen Requirements were changed.
Specimen Requirements (Specimen Container) were changed.
Specimen Requirements (Special Handling) were changed.
Stability was changed.
Reference Comment was changed.
Methods/CPT Codes were changed [LC-MS/MS (80342)]

Specimen Requirements: 1 mL Serum or Plasma
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: Serum: Collect sample in Red top tube
Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube.
Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.
Rejection Criteria: Polymer gel separation tube (SST or PST).

Test Updates

Test Changes

Stability: Room Temperature: 14 day(s)
Refrigerated: 14 day(s)
Frozen (-20 °C): 14 day(s)
Scope of Analysis: LC-MS/MS (80342): Acetophenazine
Method (CPT Code)

Compound Name	Units	Reference Comment
Acetophenazine	ng/mL	Acetophenazine was a first-generation phenothiazine previously used as an antipsychotic. It antagonizes dopamine D2 receptors. Adverse effects may include dry mouth, constipation, urinary retention and sedation.

54140B Amoxapine Confirmation (DUID/DRE), Blood

Summary of Changes: Specimen Requirements were changed.
Specimen Requirements (Specimen Container) were changed.
Stability was changed.
Reference Comment was changed.
Methods/CPT Codes were changed [LC-MS/MS (80355, 80362, 80376)]

Specimen Requirements: 1 mL Blood
Transport Temperature: Refrigerated
Specimen Container: Lavender top tube (EDTA)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: None
Stability: Room Temperature: 14 day(s)
Refrigerated: 14 day(s)
Frozen (-20 °C): 14 day(s)
Scope of Analysis: LC-MS/MS (80355, 80362, 80376): Amoxapine
Method (CPT Code)

Compound Name	Units	Reference Comment
Amoxapine	ng/mL	Reported serum concentrations of amoxapine following stabilization with 300 mg daily for 3 weeks ranged from 17 - 93 ng/mL. The ratio of whole blood concentration to serum or plasma concentration is unknown for this analyte.

52239B Amoxapine Confirmation, Blood

Summary of Changes: Specimen Requirements were changed.
Specimen Requirements (Specimen Container) were changed.
Stability was changed.
Reference Comment was changed.
Methods/CPT Codes were changed [LC-MS/MS (80335)]

Test Updates

Test Changes

Specimen Requirements:	1 mL Blood
Transport Temperature:	Refrigerated
Specimen Container:	Lavender top tube (EDTA)
Light Protection:	Not Required
Special Handling:	None
Rejection Criteria:	None
Stability:	Room Temperature: 14 day(s) Refrigerated: 14 day(s) Frozen (-20 °C): 14 day(s)
Scope of Analysis: Method (CPT Code)	LC-MS/MS (80335): Amoxapine

Compound Name	Units	Reference Comment
Amoxapine	ng/mL	Reported serum concentrations of amoxapine following stabilization with 300 mg daily for 3 weeks ranged from 17 - 93 ng/mL. The ratio of whole blood concentration to serum or plasma concentration is unknown for this analyte.

52239FL Amoxapine Confirmation, Fluid

Summary of Changes:	Specimen Requirements were changed. Methods/CPT Codes were changed [LC-MS/MS (80335)]

Specimen Requirements:	2 mL Fluid
Transport Temperature:	Refrigerated
Specimen Container:	Plastic container (preservative-free)
Light Protection:	Not Required
Special Handling:	None
Rejection Criteria:	None
Scope of Analysis: Method (CPT Code)	LC-MS/MS (80335): Amoxapine

52239SP Amoxapine Confirmation, Serum/Plasma

Summary of Changes:	Specimen Requirements were changed. Stability was changed. Reference Comment was changed. Methods/CPT Codes were changed [LC-MS/MS (80335)]

Test Updates

Test Changes

Specimen Requirements:	1 mL Serum or Plasma
Transport Temperature:	Refrigerated
Specimen Container:	Plastic container (preservative-free)
Light Protection:	Not Required
Special Handling:	Serum: Collect sample in Red top tube Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube. Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.
Rejection Criteria:	Polymer gel separation tube (SST or PST).
Stability:	Room Temperature: 14 day(s) Refrigerated: 14 day(s) Frozen (-20 °C): 14 day(s)
Scope of Analysis: Method (CPT Code)	LC-MS/MS (80335): Amoxapine

Compound Name	Units	Reference Comment
Amoxapine	ng/mL	Reported serum concentrations of amoxapine following stabilization with 300 mg daily for 3 weeks ranged from 17 - 93 ng/mL.

52239TI Amoxapine Confirmation, Tissue

Summary of Changes:	Methods/CPT Codes were changed [LC-MS/MS (80335)]
Scope of Analysis: Method (CPT Code)	LC-MS/MS (80335): Amoxapine

0325B Amoxapine and Metabolite, Blood

Summary of Changes:	Specimen Requirements were changed. Specimen Requirements (Specimen Container) were changed. Stability was changed. Reference Comment was changed. Methods/CPT Codes were changed [LC-MS/MS (80335)]
Specimen Requirements:	2 mL Blood
Transport Temperature:	Refrigerated
Specimen Container:	Lavender top tube (EDTA)
Light Protection:	Not Required
Special Handling:	None
Rejection Criteria:	None
Stability:	Room Temperature: 14 day(s) Refrigerated: 14 day(s) Frozen (-20 °C): 14 day(s)

Test Updates

Test Changes

Scope of Analysis: LC-MS/MS (80335): Amoxapine, 8-Hydroxy Amoxapine
Method (CPT Code)

Compound Name	Units	Reference Comment
Amoxapine	ng/mL	Reported serum concentrations of amoxapine following stabilization with 300 mg daily for 3 weeks ranged from 17 - 93 ng/mL. The ratio of whole blood concentration to serum or plasma concentration is unknown for this analyte.
8-Hydroxy Amoxapine	ng/mL	Reported serum concentrations of 8-hydroxyamoxapine following stabilization with 300 mg daily for 3 weeks ranged from 160 to 510 ng/mL. The ratio of whole blood concentration to serum or plasma concentration is unknown for this analyte.

0325SP Amoxapine and Metabolite, Serum/Plasma

Summary of Changes: Specimen Requirements were changed.
Specimen Requirements (Special Handling) were changed.
Stability was changed.
Reference Comment was changed.
Methods/CPT Codes were changed [LC-MS/MS (80335)]

Specimen Requirements: 1 mL Serum or Plasma
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: Serum: Collect sample in Red top tube
Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube.
Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.
Rejection Criteria: Polymer gel separation tube (SST or PST).
Stability: Room Temperature: 14 day(s)
Refrigerated: 14 day(s)
Frozen (-20 °C): 14 day(s)
Scope of Analysis: LC-MS/MS (80335): Amoxapine, 8-Hydroxy Amoxapine
Method (CPT Code)

Compound Name	Units	Reference Comment
Amoxapine	ng/mL	Reported serum concentrations of amoxapine following stabilization with 300 mg daily for 3 weeks ranged from 17 - 93 ng/mL.
8-Hydroxy Amoxapine	ng/mL	Reported serum concentrations of 8-hydroxyamoxapine following stabilization with 300 mg daily for 3 weeks ranged from 160 to 510 ng/mL.

Test Updates

Test Changes

0585B Benzonatate, Blood

Summary of Changes:
Specimen Requirements were changed.
Specimen Requirements (Transport Temperature) were changed.
Specimen Requirements (Specimen Container) were changed.
Specimen Requirements (Rejection Criteria) were changed.
Stability was changed.
Reference Comment was changed.
Methods/CPT Codes were changed [LC-MS/MS (80375)]

Specimen Requirements: 1 mL Blood
Transport Temperature: Frozen
Specimen Container: Lavender top tube (EDTA)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: Received Room Temperature. Received Refrigerated.
Stability: Room Temperature: Not Stable
Refrigerated: 2 day(s)
Frozen (-20 °C): 14 day(s)
Scope of Analysis: Method (CPT Code): LC-MS/MS (80375): Benzonatate

Compound Name	Units	Reference Comment
Benzonatate	mcg/mL	In two documented fatalities due to benzonatate, postmortem blood concentrations of 4 and 22 mcg/mL were reported. The blood to plasma ratio is not known.

0585SP Benzonatate, Serum/Plasma

Summary of Changes:
Specimen Requirements were changed.
Specimen Requirements (Transport Temperature) were changed.
Specimen Requirements (Specimen Container) were changed.
Specimen Requirements (Special Handling) were changed.
Specimen Requirements (Rejection Criteria) were changed.
Stability was changed.
Reference Comment was changed.
Methods/CPT Codes were changed [LC-MS/MS (80375)]

NMS Labs
3701 Welsh Road, PO Box 433A
Willow Grove, PA 19090-0437
nms@nmslabs.com

Test Updates

Test Changes

Specimen Requirements:	1 mL Serum or Plasma
Transport Temperature:	Frozen
Specimen Container:	Plastic container (preservative-free)
Light Protection:	Not Required
Special Handling:	Serum: Collect sample in Red top tube Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube. Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.
Rejection Criteria:	Received Room Temperature. Received Refrigerated. Polymer gel separation tube (SST or PST).
Stability:	Room Temperature: Not Stable Refrigerated: 2 day(s) Frozen (-20 °C): 14 day(s)
Scope of Analysis: Method (CPT Code)	LC-MS/MS (80375): Benzonatate

Compound Name	Units	Reference Comment
Benzonatate	mcg/mL	In two documented fatalities due to benzonatate, postmortem blood concentrations of 4 and 22 mcg/mL were reported. The blood to plasma ratio is not known.

0585U Benzonatate, Urine

Summary of Changes:	Specimen Requirements were changed. Stability was changed. Methods/CPT Codes were changed [LC-MS/MS (80375)]

Specimen Requirements:	1 mL Urine
Transport Temperature:	Refrigerated
Specimen Container:	Plastic container (preservative-free)
Light Protection:	Not Required
Special Handling:	None
Rejection Criteria:	None
Stability:	Room Temperature: 14 day(s) Refrigerated: 14 day(s) Frozen (-20 °C): 14 day(s)
Scope of Analysis: Method (CPT Code)	LC-MS/MS (80375): Benzonatate

52016U Carbromal Confirmation, Urine

Summary of Changes:	Specimen Requirements were changed.

Test Updates

Test Changes

Specimen Requirements: 3 mL Urine
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: None

1440B Dapsone and Metabolite, Blood

Summary of Changes: Specimen Requirements were changed.
Specimen Requirements (Specimen Container) were changed.
Reference Comment was changed.
Methods/CPT Codes were changed [LC-MS/MS (80375)]

Specimen Requirements: 1 mL Blood
Transport Temperature: Refrigerated
Specimen Container: Lavender top tube (EDTA)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: None
Scope of Analysis: Method (CPT Code) LC-MS/MS (80375): Dapsone, Monoacetyldapsone, Monoacetyldapsone to Dapsone Ratio

Compound Name	Units	Reference Comment
Dapsone	mcg/mL	Steady-state plasma concentrations from patients on 200 mg daily antileprotic therapy: 0.1 - 7.0 mcg/mL (mean = 2.3 mcg/mL). The blood to plasma ratio is approximately 1.0.
Monoacetyldapsone	mcg/mL	Monoacetyldapsone is an active metabolite of dapsone with antibacterial activity.
Monoacetyldapsone to Dapsone Ratio		Monoacetyldapsone to Dapsone Ratio (for acetylation phenotyping purposes): Slow acetylator: <0.35 Rapid acetylator: >0.35

1440SP Dapsone and Metabolite, Serum/Plasma

Summary of Changes: Specimen Requirements were changed.
Specimen Requirements (Specimen Container) were changed.
Specimen Requirements (Special Handling) were changed.
Stability was changed.
Reference Comment was changed.
Methods/CPT Codes were changed [LC-MS/MS (80375)]

Test Updates

Test Changes

Specimen Requirements:	1 mL Serum or Plasma
Transport Temperature:	Refrigerated
Specimen Container:	Plastic container (preservative-free)
Light Protection:	Not Required
Special Handling:	Serum: Collect sample in Red top tube Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube. Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.
Rejection Criteria:	Polymer gel separation tube (SST or PST).
Stability:	Room Temperature: 7 day(s) Refrigerated: 14 day(s) Frozen (-20 °C): 14 day(s)
Scope of Analysis: Method (CPT Code)	LC-MS/MS (80375): Dapsone, Monoacetyldapsone, Monoacetyldapsone to Dapsone Ratio

Compound Name	Units	Reference Comment
Monoacetyldapsone	mcg/mL	Monoacetyldapsone is an active metabolite of dapsone with antibacterial activity.
Monoacetyldapsone to Dapsone Ratio		Monoacetyldapsone to Dapsone Ratio (for acetylation phenotyping purposes): Slow acetylator: <0.35 Rapid acetylator: >0.35

1777B Dipyridamole, Blood

Summary of Changes:	Reference Comment was changed. Methods/CPT Codes were changed [LC-MS/MS (80375)]
Scope of Analysis: Method (CPT Code)	LC-MS/MS (80375): Dipyridamole

Compound Name	Units	Reference Comment
Dipyridamole	mcg/mL	Steady-state trough plasma concentrations following a three times daily regimen of 50 mg: 0.85 +/- 0.50 mcg/mL. The blood to plasma ratio is approximately 0.7.

1777SP Dipyridamole, Serum/Plasma

Summary of Changes:	Specimen Requirements were changed. Reference Comment was changed. Methods/CPT Codes were changed [LC-MS/MS (80375)]

Test Updates

Test Changes

Specimen Requirements:	1 mL Serum or Plasma
Transport Temperature:	Refrigerated
Specimen Container:	Plastic container (preservative-free)
Light Protection:	Not Required
Special Handling:	Serum: Collect sample in Red top tube Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube. Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.
Rejection Criteria:	Polymer gel separation tube (SST or PST).
Scope of Analysis: Method (CPT Code)	LC-MS/MS (80375): Dipyridamole

Compound Name	Units	Reference Comment
Dipyridamole	mcg/mL	Steady-state trough plasma concentrations following a three times daily regimen of 50 mg: 0.85 +/- 0.50 mcg/mL.

54351U Flecainide Confirmation (Qualitative) (DUID/DRE), Urine

Summary of Changes:	Methods/CPT Codes were changed [LC-MS/MS (80375)]
Scope of Analysis: Method (CPT Code)	LC-MS/MS (80375): Flecainide

52047B Flecainide Confirmation, Blood

Summary of Changes:	Reference Comment was changed. Methods/CPT Codes were changed [LC-MS/MS (80375)]
Scope of Analysis: Method (CPT Code)	LC-MS/MS (80375): Flecainide

Compound Name	Units	Reference Comment
Flecainide	mcg/mL	Therapeutic range to suppress PVCs: 0.2 - 1.0 mcg/mL plasma. The blood to plasma ratio is unknown.

52047FL Flecainide Confirmation, Fluid

Summary of Changes:	Methods/CPT Codes were changed [LC-MS/MS (80375)]
Scope of Analysis: Method (CPT Code)	LC-MS/MS (80375): Flecainide

52047SP Flecainide Confirmation, Serum/Plasma

Summary of Changes:	Specimen Requirements were changed. Methods/CPT Codes were changed [LC-MS/MS (80375)]

Test Updates

Test Changes

Specimen Requirements:	1 mL Serum or Plasma
Transport Temperature:	Refrigerated
Specimen Container:	Plastic container (preservative-free)
Light Protection:	Not Required
Special Handling:	Serum: Collect sample in Red top tube Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube. Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.
Rejection Criteria:	Polymer gel separation tube (SST or PST).
Scope of Analysis: Method (CPT Code)	LC-MS/MS (80375): Flecainide

52047TI Flecainide Confirmation, Tissue

Summary of Changes:	Methods/CPT Codes were changed [LC-MS/MS (80375)]
Scope of Analysis: Method (CPT Code)	LC-MS/MS (80375): Flecainide

52047U Flecainide Confirmation, Urine

Summary of Changes:	Methods/CPT Codes were changed [LC-MS/MS (80375)]
Scope of Analysis: Method (CPT Code)	LC-MS/MS (80375): Flecainide

2088B Flecainide, Blood

Summary of Changes:	Reference Comment was changed. Methods/CPT Codes were changed [LC-MS/MS (80375)]
Scope of Analysis: Method (CPT Code)	LC-MS/MS (80375): Flecainide

Compound Name	Units	Reference Comment
Flecainide	mcg/mL	Therapeutic range to suppress PVCs: 0.2 - 1.0 mcg/mL plasma. The blood to plasma ratio is unknown.

2088SP Flecainide, Serum/Plasma

Summary of Changes:	Specimen Requirements were changed. Methods/CPT Codes were changed [LC-MS/MS (80375)]

Test Updates

Test Changes

Specimen Requirements:	1 mL Serum or Plasma
Transport Temperature:	Refrigerated
Specimen Container:	Plastic container (preservative-free)
Light Protection:	Not Required
Special Handling:	Serum: Collect sample in Red top tube Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube. Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.
Rejection Criteria:	Polymer gel separation tube (SST or PST).
Scope of Analysis: Method (CPT Code)	LC-MS/MS (80375): Flecainide

2088U Flecainide, Urine

Summary of Changes:	Methods/CPT Codes were changed [LC-MS/MS (80375)]
Scope of Analysis: Method (CPT Code)	LC-MS/MS (80375): Flecainide

54357B Loxapine Confirmation (DUID/DRE), Blood

Summary of Changes:	Reference Comment was changed. Methods/CPT Codes were changed [LC-MS/MS (80342)]
Scope of Analysis: Method (CPT Code)	LC-MS/MS (80342): Loxapine

Compound Name	Units	Reference Comment
Loxapine	ng/mL	With a single 30 mg dose the plasma concentrations at approximately 1 hour averaged 20 ng/mL and 25 ng/mL for intramuscular and oral dose, respectively. The average peak plasma concentration after a single 30 mg oral inhalation dose was 58 +/- 62 ng/mL at approximately 10 minutes. The blood to plasma ratio is not known.

52064B Loxapine Confirmation, Blood

Summary of Changes:	Reference Comment was changed.
Scope of Analysis: Method (CPT Code)	LC-MS/MS (80342): Loxapine

Test Updates

Test Changes

Compound Name	Units	Reference Comment
Loxapine	ng/mL	With a single 30 mg dose the plasma concentrations at approximately 1 hour averaged 20 ng/mL and 25 ng/mL for intramuscular and oral dose, respectively. The average peak plasma concentration after a single 30 mg oral inhalation dose was 58 +/- 62 ng/mL at approximately 10 minutes. The blood to plasma ratio is not known.

52064FL Loxapine Confirmation, Fluid

Summary of Changes: Specimen Requirements were changed.

Specimen Requirements: 2 mL Fluid
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: None

52064SP Loxapine Confirmation, Serum/Plasma

Summary of Changes: Stability was changed.
Reference Comment was changed.

Stability: Room Temperature: 14 day(s)
Refrigerated: 30 day(s)
Frozen (-20 °C): 6 month(s)
Scope of Analysis: Method (CPT Code): LC-MS/MS (80342): Loxapine

Compound Name	Units	Reference Comment
Loxapine	ng/mL	With a single 30 mg dose the plasma concentrations at approximately 1 hour averaged 20 ng/mL and 25 ng/mL for intramuscular and oral dose, respectively. The average peak plasma concentration after a single 30 mg oral inhalation dose was 58 +/- 62 ng/mL at approximately 10 minutes.

2538B Loxapine, Blood

Summary of Changes: Reference Comment was changed.

Scope of Analysis: Method (CPT Code): LC-MS/MS (80342): Loxapine

NMS Labs
3701 Welsh Road, PO Box 433A
Willow Grove, PA 19090-0437
nms@nmslabs.com

Test Updates

Test Changes

Compound Name	Units	Reference Comment
Loxapine	ng/mL	With a single 30 mg dose the plasma concentrations at approximately 1 hour averaged 20 ng/mL and 25 ng/mL for intramuscular and oral dose, respectively. The average peak plasma concentration after a single 30 mg oral inhalation dose was 58 +/- 62 ng/mL at approximately 10 minutes. The blood to plasma ratio is not known.

2538SP Loxapine, Serum/Plasma

Summary of Changes: Stability was changed.
Reference Comment was changed.

Stability: Room Temperature: 14 day(s)
Refrigerated: 30 day(s)
Frozen (-20 °C): 6 month(s)

Scope of Analysis: Method (CPT Code): LC-MS/MS (80342): Loxapine

Compound Name	Units	Reference Comment
Loxapine	ng/mL	With a single 30 mg dose the plasma concentrations at approximately 1 hour averaged 20 ng/mL and 25 ng/mL for intramuscular and oral dose, respectively. The average peak plasma concentration after a single 30 mg oral inhalation dose was 58 +/- 62 ng/mL at approximately 10 minutes.

52081B Metoclopramide Confirmation, Blood

Summary of Changes: Specimen Requirements were changed.
Stability was changed.
Reference Comment was changed.
Methods/CPT Codes were changed [LC-MS/MS (80375)]

Specimen Requirements: 1 mL Blood
Transport Temperature: Refrigerated
Specimen Container: Lavender top tube (EDTA)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: None
Stability: Room Temperature: 14 day(s)
Refrigerated: 14 day(s)
Frozen (-20 °C): 14 day(s)
Scope of Analysis: Method (CPT Code): LC-MS/MS (80375): Metoclopramide

NMS Labs
3701 Welsh Road, PO Box 433A
Willow Grove, PA 19090-0437
nms@nmslabs.com

Test Updates

Test Changes

Compound Name	Units	Reference Comment
Metoclopramide	ng/mL	Daily treatment with 20 mg for 8 days produced peak plasma concentrations of 44 +/- 15 ng/mL. The blood to plasma ratio is approximately 1.0.

52081FL Metoclopramide Confirmation, Fluid

Summary of Changes: Specimen Requirements were changed.
Methods/CPT Codes were changed [LC-MS/MS (80375)]

Specimen Requirements: 2 mL Fluid
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: None
Scope of Analysis: Method (CPT Code): LC-MS/MS (80375): Metoclopramide

52081SP Metoclopramide Confirmation, Serum/Plasma

Summary of Changes: Specimen Requirements were changed.
Stability was changed.
Reference Comment was changed.
Methods/CPT Codes were changed [LC-MS/MS (80375)]

Specimen Requirements: 1 mL Serum or Plasma
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: Serum: Collect sample in Red top tube
Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube.
Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.
Rejection Criteria: Polymer gel separation tube (SST or PST).
Stability: Room Temperature: 7 day(s)
Refrigerated: 1 month(s)
Frozen (-20 °C): 4 month(s)
Scope of Analysis: Method (CPT Code): LC-MS/MS (80375): Metoclopramide

Compound Name	Units	Reference Comment
Metoclopramide	ng/mL	Daily treatment with 20 mg for 8 days produced peak plasma concentrations of 44 +/- 15 ng/mL.

Test Updates

Test Changes

52081TI Metoclopramide Confirmation, Tissue

Summary of Changes: Methods/CPT Codes were changed [LC-MS/MS (80375)]

Scope of Analysis: Method (CPT Code): LC-MS/MS (80375): Metoclopramide

52081U Metoclopramide Confirmation, Urine

Summary of Changes:
Specimen Requirements were changed.
Specimen Requirements (Specimen Container) were changed.
Methods/CPT Codes were changed [LC-MS/MS (80375)]

Specimen Requirements: 1 mL Urine
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: None
Scope of Analysis: Method (CPT Code): LC-MS/MS (80375): Metoclopramide

3041B Metoclopramide, Blood

Summary of Changes:
Specimen Requirements were changed.
Stability was changed.
Reference Comment was changed.
Methods/CPT Codes were changed [LC-MS/MS (80375)]

Specimen Requirements: 1 mL Blood
Transport Temperature: Refrigerated
Specimen Container: Lavender top tube (EDTA)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: None
Stability:
Room Temperature: 14 day(s)
Refrigerated: 14 day(s)
Frozen (-20 °C): 14 day(s)
Scope of Analysis: Method (CPT Code): LC-MS/MS (80375): Metoclopramide

Compound Name	Units	Reference Comment
Metoclopramide	ng/mL	Daily treatment with 20 mg for 8 days produced peak plasma concentrations of 44 +/- 15 ng/mL. The blood to plasma ratio is approximately 1.0.

Test Updates

Test Changes

3041SP Metoclopramide, Serum/Plasma

Summary of Changes:	Specimen Requirements were changed. Stability was changed. Reference Comment was changed. Methods/CPT Codes were changed [LC-MS/MS (80375)]

Specimen Requirements:	1 mL Serum or Plasma
Transport Temperature:	Refrigerated
Specimen Container:	Plastic container (preservative-free)
Light Protection:	Not Required
Special Handling:	Serum: Collect sample in Red top tube Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube. Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.
Rejection Criteria:	Polymer gel separation tube (SST or PST).
Stability:	Room Temperature: 7 day(s) Refrigerated: 1 month(s) Frozen (-20 °C): 4 month(s)
Scope of Analysis: Method (CPT Code)	LC-MS/MS (80375): Metoclopramide

Compound Name	Units	Reference Comment
Metoclopramide	ng/mL	Daily treatment with 20 mg for 8 days produced peak plasma concentrations of 44 +/- 15 ng/mL.

3041U Metoclopramide, Urine

Summary of Changes:	Specimen Requirements were changed. Specimen Requirements (Specimen Container) were changed. Methods/CPT Codes were changed [LC-MS/MS (80375)]

Specimen Requirements:	1 mL Urine
Transport Temperature:	Refrigerated
Specimen Container:	Plastic container (preservative-free)
Light Protection:	Not Required
Special Handling:	None
Rejection Criteria:	None
Scope of Analysis: Method (CPT Code)	LC-MS/MS (80375): Metoclopramide

3092SP Moricizine, Serum/Plasma

Test Changes

Summary of Changes: Specimen Requirements were changed.
Stability was changed.
Reference Comment was changed.
Methods/CPT Codes were changed [LC-MS/MS (80375)]

Specimen Requirements: 1 mL Serum or Plasma
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: Serum: Collect sample in Red top tube
Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube.
Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.
Rejection Criteria: Polymer gel separation tube (SST or PST).
Stability: Room Temperature: 7 day(s)
Refrigerated: 14 day(s)
Frozen (-20 °C): 8 month(s)
Scope of Analysis: Method (CPT Code) LC-MS/MS (80375): Moricizine

Compound Name	Units	Reference Comment
Moricizine	mcg/mL	Doses of 250 mg every 8 hours for 7 days produced peak plasma concentrations of 0.5 mcg/mL at approximately 0.9 hours post dose.

3145B Nefazodone, Blood

Summary of Changes: Reference Comment was changed.
Methods/CPT Codes were changed [LC-MS/MS (80338)]

Scope of Analysis: Method (CPT Code) LC-MS/MS (80338): Nefazodone

Compound Name	Units	Reference Comment
Nefazodone	mcg/mL	Peak steady-state plasma concentrations averaged 2.0 mcg/mL at approximately 0.7 hours following 200 mg daily nefazodone for 8 days. The blood to plasma ratio is unknown.

3145SP Nefazodone, Serum/Plasma

Summary of Changes: Specimen Requirements were changed.
Reference Comment was changed.
Methods/CPT Codes were changed [LC-MS/MS (80338)]

Test Updates

Test Changes

Specimen Requirements:	1 mL Serum or Plasma
Transport Temperature:	Refrigerated
Specimen Container:	Plastic container (preservative-free)
Light Protection:	Not Required
Special Handling:	Serum: Collect sample in Red top tube Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube. Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.
Rejection Criteria:	Polymer gel separation tube (SST or PST).
Scope of Analysis: Method (CPT Code)	LC-MS/MS (80338): Nefazodone

Compound Name	Units	Reference Comment
Nefazodone	mcg/mL	Peak steady-state plasma concentrations averaged 2.0 mcg/mL at approximately 0.7 hours following 200 mg daily nefazodone for 8 days.

3145U Nefazodone, Urine

Summary of Changes:	Specimen Requirements (Rejection Criteria) were changed. Stability was changed. Methods/CPT Codes were changed [LC-MS/MS (80338)]

Specimen Requirements:	1 mL Urine
Transport Temperature:	Refrigerated
Specimen Container:	Plastic container (preservative-free)
Light Protection:	Not Required
Special Handling:	None
Rejection Criteria:	Received Frozen.
Stability:	Room Temperature: 7 day(s) Refrigerated: 14 day(s) Frozen (-20 °C): Not Stable Not stable for multiple freeze/thaw cycles
Scope of Analysis: Method (CPT Code)	LC-MS/MS (80338): Nefazodone

10101U Novel Psychoactive Substances (NPS) (Qualitative), Urine (CSA)

Test Updates

Test Changes

Summary of Changes:	Scope of Analysis was changed. cis-3-Methylfentanyl, Cyclopropylfentanyl, Isobutyrylfentanyl, meta-Methylmethoxyacetylfentanyl, Methoxyacetylfentanyl, para-Fluorobutyrylfentanyl, para-Fluoroisobutyrylfentanyl, para-Methylmethoxyacetylfentanyl, THF-F, trans-3-Methylfentanyl, U-49900 and U-51754 were added. 4-Methoxybutyryl Fentanyl, AH-7921, alpha-Methyl Fentanyl, Beta-hydroxythiofentanyl, MT-45, para-Fluorobutyryl Fentanyl/FIBF and U-50488 were removed.
Scope of Analysis: Method (CPT Code)	LC/TOF-MS (80371): 2-Furanylfentanyl, 3-Fluorophenmetrazine, 3-MeO-PCP, 4-ANPP, 4-MeO-PCP, 25B-NBOMe, 25C-NBOMe, 25H-NBOMe, 25I-NBOMe, Acetyl Fentanyl, Acryl Fentanyl, alpha-PVP, Bromazepam, Butylone, Butyrylfentanyl, BZP, Carfentanil, cis-3-Methylfentanyl, Clephedrone, Clonazolam, Cyclopropylfentanyl, Delorazepam, Deschloroetizolam, Dibutylone, Diclazepam, Ethylone, Etizolam, Flubromazepam, Flubromazolam, Isobutyrylfentanyl, MDPV, Meclonazepam, meta-Methylmethoxyacetylfentanyl, Methoxyacetylfentanyl, Mephedrone, Methoxetamine, Methoxphenidine, Methylone, Mitragynine, MPHP, N-Ethyl Pentylone, ortho-Fluorofentanyl, para-Fluorobutyrylfentanyl, para-Fluorofentanyl, para-Fluoroisobutyrylfentanyl, para-Methylmethoxyacetylfentanyl, Pentedrone, Pentylone, Phenazepam, Pyrazolam, THF-F, TFMPP, trans-3-Methylfentanyl, U-47700, U-49900, U-51754, Valeryl Fentanyl GC/MS (80371): 2C-B-FLY, 2C-B, 2C-C, 2C-E, 2C-H, 2C-I, 2C-N, 2C-P, 2C-T-2, 2C-T-4, 2C-T-7, 3,4-DMMC, 4-MEC, 4-MTA, 5-IAI, 5-MeO-DALT, 5-MeO-DiPT, 5-MeO-DMT, 5-MeO-MiPT, Alpha PBP, Alpha PPP, alpha-PVT, APB, APDB, BDB, Brephedrone, Cathinone, DBZP, DET, Dimethylone, DMA, DMT, DOB, DOM, Ethylamphetamine, Ethylethcathinone, Ethylphenidate, Fluoroamphetamine, Fluoromethamphetamine, MAPB, MBDB, MBZP, MDAI, MDPBP, MDPPP, MeOPP, MeOPPP, Methcathinone, Methedrone, Methiopropamine, MPBP, Naphyrone, PMA, PMMA, Pyrovalerone, Other Findings

Compound Name	Units	Reference Comment
cis-3-Methylfentanyl	ng/mL	
Cyclopropylfentanyl	ng/mL	
Isobutyrylfentanyl	ng/mL	
meta-Methylmethoxyacetylfentanyl	ng/mL	
Methoxyacetylfentanyl	ng/mL	
para-Fluorobutyrylfentanyl	ng/mL	
para-Fluoroisobutyrylfentanyl	ng/mL	
para-Methylmethoxyacetylfentanyl	ng/mL	
THF-F	ng/mL	
trans-3-Methylfentanyl	ng/mL	
U-49900	ng/mL	
U-51754	ng/mL	

3232B Omeprazole / Esomeprazole, Blood

Test Updates

Test Changes

Summary of Changes:	Test Name was changed. Specimen Requirements were changed. Specimen Requirements (Transport Temperature) were changed. Specimen Requirements (Specimen Container) were changed. Specimen Requirements (Rejection Criteria) were changed. Stability was changed. Scope of Analysis was changed. Omeprazole / Esomeprazole was added. Methods/CPT Codes were changed [LC-MS/MS (80375)] Omeprazole was removed.

Specimen Requirements:	1 mL Blood
Transport Temperature:	Refrigerated
Specimen Container:	Lavender top tube (EDTA)
Light Protection:	Not Required
Special Handling:	None
Rejection Criteria:	None
Stability:	Room Temperature: 14 day(s) Refrigerated: 14 day(s) Frozen (-20 °C): 14 day(s)
Scope of Analysis: Method (CPT Code)	LC-MS/MS (80375): Omeprazole / Esomeprazole

Compound Name	Units	Reference Comment
Omeprazole / Esomeprazole	mcg/mL	Peak plasma concentrations at 0.4 hours following a single 20 mg dose of esomeprazole: 0.58 mcg/mL and 1.9 hours following a single 20 mg dose of omeprazole: 0.21 mcg/mL. This test is not chiral specific and cannot distinguish between omeprazole and esomeprazole. The blood to plasma ratio of omeprazole is approximately 0.6.

3232SP Omeprazole / Esomeprazole, Serum/Plasma

Summary of Changes:	Test Name was changed. Specimen Requirements were changed. Specimen Requirements (Transport Temperature) were changed. Specimen Requirements (Specimen Container) were changed. Specimen Requirements (Special Handling) were changed. Stability was changed. Scope of Analysis was changed. Omeprazole / Esomeprazole was added. Methods/CPT Codes were changed [LC-MS/MS (80375)] Omeprazole was removed.

Test Changes

Specimen Requirements:	1 mL Serum or Plasma
Transport Temperature:	Refrigerated
Specimen Container:	Plastic container (preservative-free)
Light Protection:	Not Required
Special Handling:	Serum: Collect sample in Red top tube Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube. Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.
Rejection Criteria:	Received Room Temperature. Polymer gel separation tube (SST or PST).
Stability:	Room Temperature: 2 day(s) Refrigerated: 14 day(s) Frozen (-20 °C): 14 day(s)
Scope of Analysis: Method (CPT Code)	LC-MS/MS (80375): Omeprazole / Esomeprazole

Compound Name	Units	Reference Comment
Omeprazole / Esomeprazole	mcg/mL	Peak plasma concentrations at 0.4 hours following a single 20 mg dose of esomeprazole: 0.58 mcg/mL and 1.9 hours following a single 20 mg dose of omeprazole: 0.21 mcg/mL. This test is not chiral specific and cannot distinguish between omeprazole and esomeprazole.

54393B Piperazine Designer Drugs Confirmation (DUID/DRE), Blood (CSA)

Summary of Changes:	Reference Comment was changed. mCPP was removed.
Scope of Analysis: Method (CPT Code)	GC/MS (80371): BZP

54340B Piperazine Designer Drugs Confirmation (DUID/DRE), Blood

Summary of Changes:	Scope of Analysis was changed. mCPP was removed.
Scope of Analysis: Method (CPT Code)	GC/MS (80371): TFMPP, BZP

54340U Piperazine Designer Drugs Confirmation (Qualitative) (DUID/DRE), Urine

Summary of Changes:	Scope of Analysis was changed. mCPP was removed.
Scope of Analysis: Method (CPT Code)	GC/MS (80371): TFMPP, BZP

52373B Piperazine Designer Drugs Confirmation, Blood

Test Updates

Test Changes

Summary of Changes:	Scope of Analysis was changed. mCPP was removed.
Scope of Analysis: Method (CPT Code)	GC/MS (80371): TFMPP, BZP

52373FL Piperazine Designer Drugs Confirmation, Fluid

Summary of Changes:	Scope of Analysis was changed. mCPP was removed.
Scope of Analysis: Method (CPT Code)	GC/MS (80371): TFMPP, BZP

52373SP Piperazine Designer Drugs Confirmation, Serum/Plasma

Summary of Changes:	Scope of Analysis was changed. mCPP was removed.
Scope of Analysis: Method (CPT Code)	GC/MS (80371): TFMPP, BZP

52373TI Piperazine Designer Drugs Confirmation, Tissue

Summary of Changes:	Scope of Analysis was changed. mCPP was removed.
Scope of Analysis: Method (CPT Code)	GC/MS (80371): TFMPP, BZP

52373U Piperazine Designer Drugs Confirmation, Urine

Summary of Changes:	Scope of Analysis was changed. mCPP was removed.
Scope of Analysis: Method (CPT Code)	GC/MS (80371): TFMPP, BZP

52108B Propafenone Confirmation, Blood

Summary of Changes:	Specimen Requirements were changed. Reference Comment was changed. Methods/CPT Codes were changed [LC-MS/MS (80375)]

Specimen Requirements:	1 mL Blood
Transport Temperature:	Refrigerated
Specimen Container:	Lavender top tube (EDTA)
Light Protection:	Not Required
Special Handling:	None
Rejection Criteria:	None

Test Updates

Test Changes

Scope of Analysis: Method (CPT Code): LC-MS/MS (80375): Propafenone

Compound Name	Units	Reference Comment
Propafenone	mcg/mL	In patients with complex ventricular ectopic activity, the mean trough plasma concentration associated with effective response was 0.76 mcg/mL and associated with intolerable side effects was 0.92 mcg/mL. The blood to plasma ratio is approximately 0.9.

52108FL Propafenone Confirmation, Fluid

Summary of Changes: Specimen Requirements were changed.
Methods/CPT Codes were changed [LC-MS/MS (80375)]

Specimen Requirements: 2 mL Fluid
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: None
Scope of Analysis: Method (CPT Code): LC-MS/MS (80375): Propafenone

52108SP Propafenone Confirmation, Serum/Plasma

Summary of Changes: Specimen Requirements were changed.
Reference Comment was changed.
Methods/CPT Codes were changed [LC-MS/MS (80375)]

Specimen Requirements: 1 mL Serum or Plasma
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: Serum: Collect sample in Red top tube
Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube.
Peak serum levels are recommended when monitoring patients because the level in the blood drops so rapidly that many negative results are found at the trough. The peak occurs at 3 to 4 hours post dose.
Rejection Criteria: Polymer gel separation tube (SST or PST).
Scope of Analysis: Method (CPT Code): LC-MS/MS (80375): Propafenone

Test Updates

Test Changes

Compound Name	Units	Reference Comment
Propafenone	mcg/mL	In patients with complex ventricular ectopic activity, the mean trough plasma concentration associated with effective response was 0.76 mcg/mL and associated with intolerable side effects was 0.92 mcg/mL.

52108TI Propafenone Confirmation, Tissue

Summary of Changes:	Methods/CPT Codes were changed [LC-MS/MS (80375)]
Scope of Analysis: Method (CPT Code)	LC-MS/MS (80375): Propafenone

52108U Propafenone Confirmation, Urine

Summary of Changes:	Specimen Requirements were changed. Stability was changed. Methods/CPT Codes were changed [LC-MS/MS (80375)]
Specimen Requirements:	1 mL Urine
Transport Temperature:	Refrigerated
Specimen Container:	Plastic container (preservative-free)
Light Protection:	Not Required
Special Handling:	None
Rejection Criteria:	None
Stability:	Room Temperature: 14 day(s) Refrigerated: 14 day(s) Frozen (-20 °C): 14 day(s) Not stable for multiple freeze/thaw cycles
Scope of Analysis: Method (CPT Code)	LC-MS/MS (80375): Propafenone

3976B Propafenone, Blood

Summary of Changes:	Specimen Requirements were changed. Reference Comment was changed. Methods/CPT Codes were changed [LC-MS/MS (80375)]

NMS Labs
3701 Welsh Road, PO Box 433A
Willow Grove, PA 19090-0437
nms@nmslabs.com

Test Changes

Specimen Requirements:	1 mL Blood
Transport Temperature:	Refrigerated
Specimen Container:	Lavender top tube (EDTA)
Light Protection:	Not Required
Special Handling:	Peak serum levels are recommended when monitoring patients because the level in the blood drops so rapidly that many negative results are found at the trough. The peak occurs at 3 to 4 hours post dose.
Rejection Criteria:	None
Scope of Analysis: Method (CPT Code)	LC-MS/MS (80375): Propafenone

Compound Name	Units	Reference Comment
Propafenone	mcg/mL	In patients with complex ventricular ectopic activity, the mean trough plasma concentration associated with effective response was 0.76 mcg/mL and associated with intolerable side effects was 0.92 mcg/mL. The blood to plasma ratio is approximately 0.9.

3976SP Propafenone, Serum/Plasma

Summary of Changes:	Specimen Requirements were changed. Reference Comment was changed. Methods/CPT Codes were changed [LC-MS/MS (80375)]

Specimen Requirements:	1 mL Serum or Plasma
Transport Temperature:	Refrigerated
Specimen Container:	Plastic container (preservative-free)
Light Protection:	Not Required
Special Handling:	Serum: Collect sample in Red top tube Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube. Peak serum levels are recommended when monitoring patients because the level in the blood drops so rapidly that many negative results are found at the trough. The peak occurs at 3 to 4 hours post dose.
Rejection Criteria:	Polymer gel separation tube (SST or PST).
Scope of Analysis: Method (CPT Code)	LC-MS/MS (80375): Propafenone

Compound Name	Units	Reference Comment
Propafenone	mcg/mL	In patients with complex ventricular ectopic activity, the mean trough plasma concentration associated with effective response was 0.76 mcg/mL and associated with intolerable side effects was 0.92 mcg/mL.

54125U Tiletamine Confirmation (Qualitative) (DUID/DRE), Urine

Test Updates

Test Changes

Summary of Changes:	Specimen Requirements were changed.

Specimen Requirements:	3 mL Urine
Transport Temperature:	Refrigerated
Specimen Container:	Plastic container (preservative-free)
Light Protection:	Not Required
Special Handling:	None
Rejection Criteria:	None

52125U Tiletamine Confirmation, Urine

Summary of Changes:	Specimen Requirements were changed.

Specimen Requirements:	3 mL Urine
Transport Temperature:	Refrigerated
Specimen Container:	Plastic container (preservative-free)
Light Protection:	Not Required
Special Handling:	None
Rejection Criteria:	None

54187B Trazodone and mCPP Confirmation (DUID/DRE), Blood

Summary of Changes:	Specimen Requirements were changed. Stability was changed. Scope of Analysis was changed. mCPP was added. Reference Comment was changed. Methods/CPT Codes were changed [LC-MS/MS (80338, 80371, 80362, 80376)]

Specimen Requirements:	1 mL Blood
Transport Temperature:	Refrigerated
Specimen Container:	Lavender top tube (EDTA)
Light Protection:	Not Required
Special Handling:	None
Rejection Criteria:	None
Stability:	Room Temperature: 7 day(s) Refrigerated: 14 day(s) Frozen (-20 °C): 14 day(s)
Scope of Analysis: Method (CPT Code)	LC-MS/MS (80338, 80371, 80362, 80376): mCPP, Trazodone

Test Updates

Test Changes

Compound Name	Units	Reference Comment
mCPP	mcg/mL	Peak steady-state concentrations of mCPP in plasma averaged 0.03 mcg/mL at approximately 8 hours post dose following 300 mg normal release trazodone for 7 days and 0.03 +/- 0.01 mcg/mL following 200 mg nefazodone for 8 days. The blood to plasma ratio is unknown.
Trazodone	mcg/mL	Steady-state plasma concentrations following daily oral doses of 300 mg immediate release trazodone ranged from 0.8 +/- 0.3 mcg/mL at trough to 3.1 +/- 0.8 mcg/mL at peak. The blood to plasma ratio is approximately 0.6.

54185U Trazodone and mCPP Confirmation (Qualitative) (DUID/DRE), Urine

Summary of Changes: Test Name was changed.
Specimen Requirements were changed.
Scope of Analysis was changed.
mCPP was added.
Methods/CPT Codes were changed [LC-MS/MS (80338, 80371, 80362, 80376)]

Specimen Requirements: 1 mL Urine
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: None
Scope of Analysis: Method (CPT Code): LC-MS/MS (80338, 80371, 80362, 80376): mCPP, Trazodone

Compound Name	Units	Reference Comment
mCPP	mcg/mL	

52295B Trazodone and mCPP Confirmation, Blood

Summary of Changes: Test Name was changed.
Specimen Requirements were changed.
Stability was changed.
Scope of Analysis was changed.
mCPP was added.
Reference Comment was changed.
Methods/CPT Codes were changed [LC-MS/MS (80338, 80371, 80362, 80376)]

NMS Labs
3701 Welsh Road, PO Box 433A
Willow Grove, PA 19090-0437
nms@nmslabs.com

Test Updates

Test Changes

Specimen Requirements:	1 mL Blood
Transport Temperature:	Refrigerated
Specimen Container:	Lavender top tube (EDTA)
Light Protection:	Not Required
Special Handling:	None
Rejection Criteria:	None
Stability:	Room Temperature: 7 day(s) Refrigerated: 14 day(s) Frozen (-20 °C): 14 day(s)
Scope of Analysis: Method (CPT Code)	LC-MS/MS (80338, 80371, 80362, 80376): mCPP, Trazodone

Compound Name	Units	Reference Comment
mCPP	mcg/mL	Peak steady-state concentrations of mCPP in plasma averaged 0.03 mcg/mL at approximately 8 hours post dose following 300 mg normal release trazodone for 7 days and 0.03 +/- 0.01 mcg/mL following 200 mg nefazodone for 8 days. The blood to plasma ratio is unknown.
Trazodone	mcg/mL	Steady-state plasma concentrations following daily oral doses of 300 mg immediate release trazodone ranged from 0.8 +/- 0.3 mcg/mL at trough to 3.1 +/- 0.8 mcg/mL at peak. The blood to plasma ratio is approximately 0.6.

52295FL Trazodone and mCPP Confirmation, Fluid

Summary of Changes:	Test Name was changed. Specimen Requirements were changed. Scope of Analysis was changed. mCPP was added. Methods/CPT Codes were changed [LC-MS/MS (80338, 80371, 80362, 80376)]

Specimen Requirements:	2 mL Fluid
Transport Temperature:	Refrigerated
Specimen Container:	Plastic container (preservative-free)
Light Protection:	Not Required
Special Handling:	None
Rejection Criteria:	None
Scope of Analysis: Method (CPT Code)	LC-MS/MS (80338, 80371, 80362, 80376): mCPP, Trazodone

Compound Name	Units	Reference Comment
mCPP	mcg/mL	

Test Updates

Test Changes

52295SP Trazodone and mCPP Confirmation, Serum/Plasma

Summary of Changes: Test Name was changed.
Specimen Requirements were changed.
Stability was changed.
Scope of Analysis was changed.
mCPP was added.
Reference Comment was changed.
Methods/CPT Codes were changed [LC-MS/MS (80338, 80371, 80362, 80376)]

Specimen Requirements: 1 mL Serum or Plasma
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: Serum: Collect sample in Red top tube
Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube.
Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.
Rejection Criteria: Polymer gel separation tube (SST or PST).
Stability: Room Temperature: 14 day(s)
Refrigerated: 14 day(s)
Frozen (-20 °C): 14 day(s)
Scope of Analysis: Method (CPT Code) LC-MS/MS (80338, 80371, 80362, 80376): mCPP, Trazodone

Compound Name	Units	Reference Comment
mCPP	mcg/mL	Peak steady-state concentrations of mCPP in plasma averaged 0.03 mcg/mL at approximately 8 hours post dose following 300 mg normal release trazodone for 7 days and 0.03 +/- 0.01 mcg/mL following 200 mg nefazodone for 8 days.
Trazodone	mcg/mL	Steady-state plasma concentrations following daily oral doses of 300 mg immediate release trazodone ranged from 0.8 +/- 0.3 mcg/mL at trough to 3.1 +/- 0.8 mcg/mL at peak.

52295TI Trazodone and mCPP Confirmation, Tissue

Summary of Changes: Test Name was changed.
Scope of Analysis was changed.
mCPP was added.
Methods/CPT Codes were changed [LC-MS/MS (80338, 80371, 80362, 80376)]

Scope of Analysis: Method (CPT Code) LC-MS/MS (80338, 80371, 80362, 80376): mCPP, Trazodone

Test Updates

Test Changes

Compound Name	Units	Reference Comment
mCPP	mcg/g	

52295U Trazodone and mCPP Confirmation, Urine

Summary of Changes: Test Name was changed.
Specimen Requirements were changed.
Scope of Analysis was changed.
mCPP was added.
Methods/CPT Codes were changed [LC-MS/MS (80338, 80371, 80362, 80376)]

Specimen Requirements: 1 mL Urine
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: None
Scope of Analysis: Method (CPT Code): LC-MS/MS (80338, 80371, 80362, 80376): mCPP, Trazodone

Compound Name	Units	Reference Comment
mCPP	mcg/mL	

4535B Trazodone and mCPP, Blood

Summary of Changes: Test Name was changed.
Stability was changed.
Scope of Analysis was changed.
mCPP was added.
Reference Comment was changed.
Methods/CPT Codes were changed [LC-MS/MS (80338, 80371)]

Stability: Room Temperature: 7 day(s)
Refrigerated: 14 day(s)
Frozen (-20 °C): 14 day(s)
Scope of Analysis: Method (CPT Code): LC-MS/MS (80338, 80371): Trazodone, mCPP

Compound Name	Units	Reference Comment
Trazodone	mcg/mL	Steady-state plasma concentrations following daily oral doses of 300 mg immediate release trazodone ranged from 0.8 +/- 0.3 mcg/mL at trough to 3.1 +/- 0.8 mcg/mL at peak. The blood to plasma ratio is approximately 0.6.

Test Updates

Test Changes

Compound Name	Units	Reference Comment
mCPP	mcg/mL	Peak steady-state concentrations of mCPP in plasma averaged 0.03 mcg/mL at approximately 8 hours post dose following 300 mg normal release trazodone for 7 days and 0.03 +/- 0.01 mcg/mL following 200 mg nefazodone for 8 days. The blood to plasma ratio is unknown.

4535SP Trazodone and mCPP, Serum/Plasma

Summary of Changes: Test Name was changed.
Specimen Requirements were changed.
Stability was changed.
Scope of Analysis was changed.
mCPP was added.
Reference Comment was changed.
Methods/CPT Codes were changed [LC-MS/MS (80338, 80371)]

Specimen Requirements: 1 mL Serum or Plasma
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: Serum: Collect sample in Red top tube
Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube.
Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.
Rejection Criteria: Polymer gel separation tube (SST or PST).
Stability: Room Temperature: 14 day(s)
Refrigerated: 14 day(s)
Frozen (-20 °C): 14 day(s)
Scope of Analysis: Method (CPT Code) LC-MS/MS (80338, 80371): Trazodone, mCPP

Compound Name	Units	Reference Comment
Trazodone	mcg/mL	Steady-state plasma concentrations following daily oral doses of 300 mg immediate release trazodone ranged from 0.8 +/- 0.3 mcg/mL at trough to 3.1 +/- 0.8 mcg/mL at peak.
mCPP	mcg/mL	Peak steady-state concentrations of mCPP in plasma averaged 0.03 mcg/mL at approximately 8 hours post dose following 300 mg normal release trazodone for 7 days and 0.03 +/- 0.01 mcg/mL following 200 mg nefazodone for 8 days.

4535U Trazodone and mCPP, Urine

Test Updates

Test Changes

Summary of Changes: Test Name was changed.
Scope of Analysis was changed.
mCPP was added.
Methods/CPT Codes were changed [LC-MS/MS (80338, 80371)]

Scope of Analysis: Method (CPT Code): LC-MS/MS (80338, 80371): Trazodone, mCPP

Compound Name	Units	Reference Comment
mCPP	mcg/mL	No reference data available.

4535FL Trazodone, Fluid

Summary of Changes: Methods/CPT Codes were changed [LC-MS/MS (80338)]

Scope of Analysis: Method (CPT Code): LC-MS/MS (80338): Trazodone

4535TI Trazodone, Tissue

Summary of Changes: Methods/CPT Codes were changed [LC-MS/MS (80338)]

Scope of Analysis: Method (CPT Code): LC-MS/MS (80338): Trazodone

4800B Warfarin, Blood

Summary of Changes: Specimen Requirements were changed.
Specimen Requirements (Specimen Container) were changed.
Reference Comment was changed.
Methods/CPT Codes were changed [LC-MS/MS (80375)]

Specimen Requirements: 1 mL Blood
Transport Temperature: Refrigerated
Specimen Container: Lavender top tube (EDTA)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: None
Scope of Analysis: Method (CPT Code): LC-MS/MS (80375): Warfarin

NMS Labs
3701 Welsh Road, PO Box 433A
Willow Grove, PA 19090-0437
nms@nmslabs.com

Test Updates

Test Changes

Compound Name	Units	Reference Comment
Warfarin	mcg/mL	The dosage of warfarin is best adjusted based on the International Normalized Ratio (INR) for prothrombin time. Peak plasma concentrations following single 10 mg doses averaged 0.6 mcg/mL for both R-warfarin and S-warfarin (combined concentration 1.2 mcg/mL). This test is not chiral specific and does not distinguish between the R and S enantiomers of warfarin. The blood to plasma ratio is approximately 0.5.

4800SP Warfarin, Serum/Plasma

Summary of Changes: Specimen Requirements were changed.
Reference Comment was changed.
Methods/CPT Codes were changed [LC-MS/MS (80375)]

Specimen Requirements: 1 mL Serum or Plasma
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: Serum: Collect sample in Red top tube
Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube.
Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.
Rejection Criteria: Polymer gel separation tube (SST or PST).
Scope of Analysis: Method (CPT Code) LC-MS/MS (80375): Warfarin

Compound Name	Units	Reference Comment
Warfarin	mcg/mL	The dosage of warfarin is best adjusted based on the International Normalized Ratio (INR) for prothrombin time. Peak plasma concentrations following single 10 mg doses averaged 0.6 mcg/mL for both R-warfarin and S-warfarin (combined concentration 1.2 mcg/mL). This test is not chiral specific and does not distinguish between the R and S enantiomers of warfarin.

54138U Zolazepam Confirmation (Qualitative) (DUID/DRE), Urine

Summary of Changes: Specimen Requirements were changed.

Test Updates

Test Changes

Specimen Requirements:	3 mL Urine
Transport Temperature:	Refrigerated
Specimen Container:	Plastic container (preservative-free)
Light Protection:	Not Required
Special Handling:	None
Rejection Criteria:	None

52138U Zolazepam Confirmation, Urine

Summary of Changes: Specimen Requirements were changed.

Specimen Requirements:	3 mL Urine
Transport Temperature:	Refrigerated
Specimen Container:	Plastic container (preservative-free)
Light Protection:	Not Required
Special Handling:	None
Rejection Criteria:	None

4875U Zolazepam, Urine

Summary of Changes: Specimen Requirements were changed.

Specimen Requirements:	3 mL Urine
Transport Temperature:	Refrigerated
Specimen Container:	Plastic container (preservative-free)
Light Protection:	Not Required
Special Handling:	None
Rejection Criteria:	None

1138B meta-Chlorophenylpiperazine (mCPP), Blood (Forensic)

Summary of Changes: Specimen Requirements were changed.
Stability was changed.
Reference Comment was changed.
Units were changed.
Methods/CPT Codes were changed [LC-MS/MS (80371)]

NMS Labs
3701 Welsh Road, PO Box 433A
Willow Grove, PA 19090-0437
nms@nmslabs.com

Test Updates

Test Changes

Specimen Requirements:	1 mL Blood
Transport Temperature:	Refrigerated
Specimen Container:	Lavender top tube (EDTA)
Light Protection:	Not Required
Special Handling:	None
Rejection Criteria:	None
Stability:	Room Temperature: 7 day(s) Refrigerated: 14 day(s) Frozen (-20 °C): 14 day(s)
Scope of Analysis: Method (CPT Code)	LC-MS/MS (80371): mCPP

Compound Name	Units	Reference Comment
mCPP	mcg/mL	Peak steady-state concentrations of mCPP in plasma averaged 0.03 mcg/mL at approximately 8 hours post dose following 300 mg normal release trazodone for 7 days and 0.03 +/- 0.01 mcg/mL following 200 mg nefazodone for 8 days. The blood to plasma ratio is unknown.

1138SP meta-Chlorophenylpiperazine (mCPP), Serum/Plasma (Forensic)

Summary of Changes:	Specimen Requirements were changed. Specimen Requirements (Special Handling) were changed. Stability was changed. Reference Comment was changed. Units were changed. Methods/CPT Codes were changed [LC-MS/MS (80371)]

Specimen Requirements:	1 mL Serum or Plasma
Transport Temperature:	Refrigerated
Specimen Container:	Plastic container (preservative-free)
Light Protection:	Not Required
Special Handling:	Serum: Collect sample in Red top tube Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube. Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.
Rejection Criteria:	Polymer gel separation tube (SST or PST).
Stability:	Room Temperature: 14 day(s) Refrigerated: 14 day(s) Frozen (-20 °C): 14 day(s)
Scope of Analysis: Method (CPT Code)	LC-MS/MS (80371): mCPP

Test Updates

Test Changes

Compound Name	Units	Reference Comment
mCPP	mcg/mL	Peak steady-state concentrations of mCPP in plasma averaged 0.03 mcg/mL at approximately 8 hours post dose following 300 mg normal release trazodone for 7 days and 0.03 +/- 0.01 mcg/mL following 200 mg nefazodone for 8 days.

1138U meta-Chlorophenylpiperazine (mCPP), Urine (Forensic)

Summary of Changes: Specimen Requirements were changed.
Stability was changed.
Reference Comment was changed.
Units were changed.
Methods/CPT Codes were changed [LC-MS/MS (80371)]

Specimen Requirements: 1 mL Urine
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: None
Stability: Room Temperature: 14 day(s)
Refrigerated: 14 day(s)
Frozen (-20 °C): 14 day(s)
Scope of Analysis: Method (CPT Code): LC-MS/MS (80371): mCPP

Compound Name	Units	Reference Comment
mCPP	mcg/mL	[Reference comment removed]

Test Updates

Discontinued Tests

Test Code	Test Name	Alternative Test
0100B	Acetophenazine, Blood	0100SP - Acetophenazine, Serum/Plasma
5448B	Amoxapine and Metabolite Confirmation, Blood	No Alternate Tests Available
5448SP	Amoxapine and Metabolite Confirmation, Serum/Plasma	No Alternate Tests Available
5448U	Amoxapine and Metabolite Confirmation, Urine	No Alternate Tests Available
9107B	Amoxapine and Metabolite Screen, Blood	0325B - Amoxapine and Metabolite, Blood
9107SP	Amoxapine and Metabolite Screen, Serum/Plasma	0325SP - Amoxapine and Metabolite, Serum/Plasma
9107U	Amoxapine and Metabolite Screen, Urine	0325U - 8-Hydroxy Amoxapine, Urine
1777U	Dipyridamole, Urine	1777SP - Dipyridamole, Serum/Plasma
5664B	Trazodone Confirmation, Blood	No Alternate Tests Available
5664SP	Trazodone Confirmation, Serum/Plasma	No Alternate Tests Available
5664U	Trazodone Confirmation, Urine	No Alternate Tests Available
9282B	Trazodone Screen, Blood	4535B - Trazodone and mCPP, Blood
9282SP	Trazodone Screen, Serum/Plasma	4535SP - Trazodone and mCPP, Serum/Plasma
9282U	Trazodone Screen, Urine	4535U - Trazodone and mCPP, Urine
0419SP	Warfarin (Qualitative), Serum/Plasma	4800SP - Warfarin, Serum/Plasma